Moorkens G, Wynants H, Abs R
Department of Internal Medicine, University Hospital Antwerp, Belgium.
Growth Horm IGF Res. 1998 Apr;8 Suppl B:131-3. doi: 10.1016/s1096-6374(98)80037-3.
The efficacy of growth hormone (GH) therapy was evaluated in patients with chronic fatigue syndrome (CFS) who had peak serum GH levels below 10 microg/l during stage-controlled sleep. Twenty patients (7 men, 13 women; age range, 30-60 years) with CFS were randomized to receive placebo or GH therapy, 6.7 microg/kg/day (0.02 IU/kg/day), for 12 weeks. Following this double-blind treatment period, the 17 patients remaining in the study were given GH therapy at the above dose for an open period of 9 months. Mean (+/- SD) serum levels of insulin-like growth factor I (IGF-I) increased during GH treatment, from 173 +/- 46 microg/I to 296 +/- 89 microg/l (P < 0.001); IGF-I SDS values increased from -0.45 +/- 1.14 to +1.43 +/- 1.09 (P < 0.001). Fat-free mass and total body water were significantly increased after 12 months of treatment. Although quality of life, as assessed using two different questionnaires, did not improve significantly during GH treatment, four patients were able to resume work after a long period of sick leave.
对慢性疲劳综合征（CFS）患者进行了生长激素（GH）治疗效果评估，这些患者在分阶段控制睡眠期间血清GH峰值水平低于10微克/升。20例CFS患者（7例男性，13例女性；年龄范围30 - 60岁）被随机分为接受安慰剂或GH治疗组，剂量为6.7微克/千克/天（0.02国际单位/千克/天），为期12周。在这个双盲治疗期之后，研究中剩余的17例患者以上述剂量接受GH治疗，为期9个月的开放治疗期。在GH治疗期间，胰岛素样生长因子I（IGF - I）的平均（±标准差）血清水平从173±46微克/升升至296±89微克/升（P < 0.001）；IGF - I SDS值从 - 0.45±1.14升至 + 1.43±1.09（P < 0.001）。治疗十二个月后，去脂体重和总体水显著增加。尽管使用两种不同问卷评估的生活质量在GH治疗期间没有显著改善，但有4例患者在长期病假后能够恢复工作。
